Michael Muzoora, MD
Pulmonary Disease · Owensboro, KYNPI 1629237458
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.8%), education and travel and lodging — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Intuitive Surgical at 38.4% of the total. Reporting peaked in 2023 at $11,139 and has fallen 89.3% since, to $1,194 in 2025. Among pulmonary disease clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 449 payments — averaging $39.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$7K
- Penumbra, Inc.$3K
- GSK$2K
- AstraZeneca$1K
- Actelion Pharmaceuticals US, Inc.$817
- Boehringer Ingelheim$539
- plus $4K from 33 others
What the payments were for
- Travel & lodging$3,02717%
- Food & beverage$8,70649%
- Education$6,12434%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 8 | $6,852 |
| Penumbra, Inc. | 9 | $2,821 |
| GSK | 110 | $1,528 |
| AstraZeneca | 55 | $1,479 |
| Actelion Pharmaceuticals US, Inc. | 32 | $817 |
| Boehringer Ingelheim | 31 | $539 |
| Sunovion Pharmaceuticals Inc. | 30 | $401 |
| Insmed, Inc. | 25 | $387 |
| Sanofi | 16 | $333 |
| Olympus America Inc. | 5 | $321 |
| Gilead | 14 | $222 |
| Electromed, Inc. | 14 | $220 |
| Regeneron Healthcare Solutions, Inc. | 13 | $219 |
| Grifols USA, LLC | 14 | $211 |
| Mylan Specialty L.p. | 12 | $183 |
| United Therapeutics Corporation | 6 | $152 |
| Amgen | 6 | $102 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Livanova USA, Inc. | 1 | $91 |
| Harmony Biosciences LLC | 3 | $89 |
| Genentech USA, Inc. | 7 | $87 |
| Merck | 6 | $84 |
| Philips North America LLC | 5 | $80 |
| Teva Pharmaceuticals USA, Inc. | 6 | $79 |
| Novartis | 3 | $73 |
| Inari Medical, Inc. | 1 | $72 |
| CSL Behring | 2 | $42 |
| Baxter Healthcare | 2 | $40 |
| Viatris Specialty LLC | 2 | $34 |
| Abiomed | 1 | $30 |
| Mayne Pharma Commercial LLC | 1 | $27 |
| Mallinckrodt Hospital Products Inc. | 1 | $26 |
| Veran Medical Technologies, Inc. | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $18 |
| AbbVie | 1 | $16 |
| Siemens Medical Solutions USA, Inc. | 1 | $14 |
| Resmed Corp | 1 | $14 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$6,810
- Indigo System$2,479
- FASENRA$767
- BREZTRI$657
- TEZSPIRE$352
- AIRSUPRA$165
- SYMBICORT$110
- Spiration Valve System$110
- FARXIGA$102
How this compares
$17,858 in reported general payments places this provider in the 90th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 227 | $174,173 |
| OpsumitMacitentan | 13 | $163,703 |
| OfevNintedanib Esylate | 12 | $155,755 |
| Spiriva RespimatTiotropium Bromide | 167 | $114,523 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 143 | $101,068 |
| ZemairaAlpha-1-Proteinase Inhibitor | 11 | $77,617 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 104 | $72,339 |
| Breo ElliptaFluticasone/Vilanterol | 135 | $71,380 |
| Spiriva HandihalerTiotropium Bromide | 55 | $43,074 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 58 | $37,849 |
| SymbicortBudesonide/Formoterol Fumarate | 113 | $33,989 |
| Advair HfaFluticasone Propion/Salmeterol | 75 | $27,339 |
| Incruse ElliptaUmeclidinium Bromide | 68 | $25,200 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 111 | $16,604 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 467 | $13,972 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $539 | $355,833309 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,528 | $313,610501 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $817 | $163,70313 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,479 | $146,544284 claims |
| CSL BehringZemaira | $42 | $77,61711 claims |
| MerckDulera | $84 | $12,83723 claims |
| PfizerEliquis | $11 | $11,88921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Owensboro
- Rejmon DedajOwensboro$14K
- Berhanemeskel NesketaOwensboro$14K
- Thomas WaringOwensboro$13K
- John McConnellLouisville$864K
- Erica GregonisRichmond$390K
- Firas KouraGeorgetown$350K
- Harold HallerLouisville$340K
- Steven KoenigMorehead$242K
- Samantha BaahLouisville$226K
- Sandra SchuldheiszSomerset$225K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.